drugset / Trial / NCT00267657

A Phase 1 Parallel-Group, Double-Blind, Placebo-Controlled Cardiovascular and Behavioral Study Assessing Interactions Between Single Doses of Oral Reserpine and Intravenous Methamphetamine - 1

NCT00267657

Phase 1 Unknown 30 enrolled National Institute on Drug Abuse (NIDA)
RandomizedParallel-groupDouble-blindTreatment

Summary

In this parallel group clinical pharmacology laboratory experiment, we will assess pharmacodynamic interactions (with a focus on cardiovascular effects) of a 15 mg intravenous methamphetamine dose and single oral doses of reserpine (0.5 and 1.0 mg) or placebo.

Timeline

Start
2004-01
Primary completion
Completion
2004-11

Drugs

EvaluationDrugModalityDoseRoute
Subject reserpine Small molecule 0.5 mg
Subject reserpine Small molecule 1 mg